Bayer Sees Significant, But Smaller, Asundexian Opportunity
BMS Still Confident In Competing Asset Milvexian
Scrip spoke with Bayer’s head of pharma R&D Christian Rommel at the J.P. Morgan Healthcare Conference about the road ahead for Factor XIa inhibitor asundexian after its atrial fibrillation setback.
